Reviewed by Brian St. Pierre, MS, RD
“Is this drug going to steal my job?”
That’s the thought many health and fitness coaches had when GLP-1 medications first hit the mass market.
Though semaglutide (Ozempic) became available in 2017, it initially felt like a theoretical threat. Prescription rates were still very low; it seemed like no one actually knew anyone who was taking it.
Now, in 2026, over 1 in 10 US adults are taking a GLP-1 medication. Most of us know someone on it (or we’re on it ourselves).
With wider use, opinions towards the medication have softened too. Most coaches no longer see it as a threat, and rather appreciate it as a valuable tool for certain clients, with coaching as an additive complement.
Many…